[Federal Register Volume 63, Number 72 (Wednesday, April 15, 1998)]
[Notices]
[Page 18431]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-9864]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 97E-0144]
Determination of Regulatory Review Period for Purposes of Patent
Extension; ZAGAM
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) has determined the
regulatory review period for ZAGAM and is publishing this
notice of that determination as required by law. FDA has made the
determination because of the submission of an application to the
Commissioner of Patents and Trademarks, Department of Commerce, for the
extension of a patent which claims that human drug product.
ADDRESSES: Written comments and petitions should be directed to the
Dockets Management Branch (HFA-305), Food and Drug Administration,
12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857.
FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health
Affairs (HFY-20), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-6620.
SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term
Restoration Act of 1984 (Pub. L. 98-417) and the Generic Animal Drug
and Patent Term Restoration Act (Pub. L. 100-670) generally provide
that a patent may be extended for a period of up to 5 years so long as
the patented item (human drug product, animal drug product, medical
device, food additive, or color additive) was subject to regulatory
review by FDA before the item was marketed. Under these acts, a
product's regulatory review period forms the basis for determining the
amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A
testing phase and an approval phase. For human drug products, the
testing phase begins when the exemption to permit the clinical
investigations of the drug becomes effective and runs until the
approval phase begins. The approval phase starts with the initial
submission of an application to market the human drug product and
continues until FDA grants permission to market the drug product.
Although only a portion of a regulatory review period may count toward
the actual amount of extension that the Commissioner of Patents and
Trademarks may award (for example, half the testing phase must be
subtracted as well as any time that may have occurred before the patent
was issued), FDA's determination of the length of a regulatory review
period for a human drug product will include all of the testing phase
and approval phase as specified in 35 U.S.C. 156(g)(1)(B).
FDA recently approved for marketing the human drug product
ZAGAM (sparfloxacin). ZAGAM is indicated for
community-acquired pneumonia and acute bacterial exacerbations of
chronic bronchitis. Subsequent to this approval, the Patent and
Trademark Office received a patent term restoration application for
ZAGAM (U.S. Patent No. 4,795,751) from Dainippon
Pharmaceutical Co., Ltd., and the Patent and Trademark Office requested
FDA's assistance in determining this patent's eligibility for patent
term restoration. In a letter dated May 21, 1997, FDA advised the
Patent and Trademark Office that this human drug product had undergone
a regulatory review period and that the approval of ZAGAM
represented the first permitted commercial marketing or use of the
product. Shortly thereafter, the Patent and Trademark Office requested
that FDA determine the product's regulatory review period.
FDA has determined that the applicable regulatory review period for
ZAGAM is 2,030 days. Of this time, 1,671 days occurred during
the testing phase of the regulatory review period, while 359 days
occurred during the approval phase. These periods of time were derived
from the following dates:
1. The date an exemption under section 505 of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355) became effective: June 1, 1991.
FDA has verified the applicant's claim that the date the
investigational new drug application became effective was on June 1,
1991.
2. The date the application was initially submitted with respect to
the human drug product under section 505 of the Federal Food, Drug, and
Cosmetic Act: December 27, 1995. FDA has verified the applicant's claim
that the new drug application (NDA) for ZAGAM (NDA 20-677)
was initially submitted on December 27, 1995.
3. The date the application was approved: December 19, 1996. FDA
has verified the applicant's claim that NDA 20-677 was approved on
December 19, 1996.
This determination of the regulatory review period establishes the
maximum potential length of a patent extension. However, the U.S.
Patent and Trademark Office applies several statutory limitations in
its calculations of the actual period for patent extension. In its
application for patent extension, this applicant seeks 1,194 days of
patent term extension.
Anyone with knowledge that any of the dates as published is
incorrect may, on or before June 15, 1998, submit to the Dockets
Management Branch (address above) written comments and ask for a
redetermination. Furthermore, any interested person may petition FDA,
on or before October 13, 1998, for a determination regarding whether
the applicant for extension acted with due diligence during the
regulatory review period. To meet its burden, the petition must contain
sufficient facts to merit an FDA investigation. (See H. Rept. 857, part
1, 98th Cong., 2d sess., pp. 41-42, 1984.) Petitions should be in the
format specified in 21 CFR 10.30.
Comments and petitions should be submitted to the Dockets
Management Branch (address above) in three copies (except that
individuals may submit single copies) and identified with the docket
number found in brackets in the heading of this document. Comments and
petitions may be seen in the Dockets Management Branch between 9 a.m.
and 4 p.m., Monday through Friday.
Dated: April 8, 1998.
Thomas J. McGinnis,
Deputy Associate Commissioner for Health Affairs.
[FR Doc. 98-9864 Filed 4-14-98; 8:45 am]
BILLING CODE 4160-01-F
